Blocking the MAPK pathway for Trk inhibitor resistant cancers

Targeting the MAPK pathway could be a key to overcoming a new mechanism of tissue-agnostic therapy resistance identified by a Memorial Sloan Kettering Cancer Center team.

FDA has approved two inhibitors of TrkA, TrkB and TrkC for tissue-agnostic treatment of solid tumors with a NTRK gene fusion: Vitrakvi larotrectinib from Loxo Oncology Inc. and Bayer AG (Xetra:BAYN) last year and Rozlytrek entrectinib from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) in August (see “Genentech gains its first U.S. tissue-agnostic approval with Rozlytrek”)...